December 7, 2022
RegMed Investors’ (RMi) pre-open: shareholders have had a “rough ride” lately
December 6, 2022
RegMed Investors’ (RMi) pre-open: an uptrend after a share pricing purge
December 5, 2022
RegMed Investors’ (RMi) pre-open: looking for more as December begins
December 2, 2022
RegMed Investors’ (RMi) pre-open: jobs report looms as go markets and sector
December 1, 2022
RegMed Investors’ (RMi) pre-open: upside action, after a surge; there’s usually a purge
November 30, 2022
RegMed Investors’ (RMi) pre-open: forget Waiting for Godot, I’m waiting for Jerome
November 29, 2022
RegMed Investors’ (RMi) pre-open: post carnage, wishful thinking
November 28, 2022
RegMed Investors’ (RMi) pre-open: Ending November this week (Wednesday)
November 25, 2022
RegMed Investors’ (RMi) pre-open: shortened trading session ends week
November 23, 2022
RegMed Investors’ (RMi) pre-open: time to travel defensively while awaiting Fed minutes
November 22, 2022
RegMed Investors’ (RMi) pre-open: be mindful of frazzled sector
November 21, 2022
RegMed Investors’ (RMi) pre-open: key word: resistance
November 18, 2022
RegMed Investors’ (RMi) pre-open: a tick or retreat Friday?
November 17, 2022
RegMed Investors’ (RMi) pre-open: following the market outlook and bouncing share pricings
November 16, 2022
RegMed Investors’ (RMi) pre-open: whatever floats your boat or fills your portfolio, short-term moves could defend your positions
November 15, 2022
RegMed Investors’ (RMi) pre-open: Monday’s whiplash leaves share pricing ready to move upward
November 14, 2022
RegMed Investors’ (RMi) pre-open: after an upside ending week
November 11, 2022
RegMed Investors’ (RMi) pre-open: post massive gains, what usually follows is pain
November 10, 2022
RegMed Investors’ (RMi) pre-open: CPI, up +0.4% versus +0.6% estimate
November 9, 2022
RegMed Investors’ (RMi) pre-open: stock futures trade lower as election results are tallied
November 8, 2022
RegMed Investors’ (RMi) pre-open: vote your conscious and your portfolio
November 7, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector is stuck in earnings LPS (loss-per-share) season
November 4, 2022
RegMed Investors’ (RMi) pre-open: We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies
November 3, 2022
RegMed Investors’ (RMi) pre-open: gains followed by pain; so, what’s on-tap - earnings
November 2, 2022
RegMed Investors’ (RMi) pre-open: bracing for Fed’s policy decision
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.